This year, the Indian government introduced an injectable contraceptive, depot medroxyprogesterone acetate (DMPA), as a part of a family planning program which seeks to improve family planning services in 145 high-focus districts. It is a progestogen-only drug injected intra-muscularly. Like most other hormonal contraceptives, DMPA has several temporary side-effects like menstrual changes, weight gain, headache, mood swings, etc. Apart from these, DMPA has long been controversial, and is being linked to many health issues like osteoporosis, breast cancer, and delayed return of fertility.
Government agencies who are in support of its use, claim its benefits compensate its risks and it will be administered with informed consent. However, there is no strong evidence available especially in Indian subjects to put the question of its suspected health risks. Also, according to the WHO’s…
